Valuation: UCB

Market Cap 40.44B 46.38B 38.09B 34.69B 65.03B 4,443B 65.11B 456B 176B 2,263B 174B 170B 7,304B P/E 2026 *
21.2x
P/E 2027 * 17.5x
Enterprise Value 40.75B 46.73B 38.38B 34.95B 65.52B 4,477B 65.61B 460B 177B 2,281B 176B 172B 7,359B EV / Sales 2026 *
4.69x
EV / Sales 2027 * 3.99x
Free-Float
61.59%
Yield 2026 *
0.69%
Yield 2027 * 0.71%
1 day-6.65%
1 week-7.23%
Current month-6.78%
1 month-11.11%
3 months-20.68%
6 months-15.33%
Current year-20.34%
1 week 228.94
Extreme 228.94
252.34
1 month 228.94
Extreme 228.94
268.09
Current year 228.94
Extreme 228.94
345.39
1 year 225.65
Extreme 225.65
345.39
3 years 69.7
Extreme 69.7
345.39
5 years 68.3
Extreme 68.301062
345.39
10 years 58.42
Extreme 58.42
345.39
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Change 5-day change 1-year change 3-year change Capi.($)
-6.65%-7.23% - - 45.5B
+1.70%+0.56%+34.83%-3.06% 78.37B
+12.27%+17.89%+585.18%+72.54% 61.5B
+1.39%+3.74%-9.27%-28.31% 59.78B
+0.29%-1.27%-10.95%+28.43% 46.53B
+1.92%+0.76%+4.33%+154.99% 45.5B
+1.66%+0.79%+53.73%-15.39% 31.84B
-0.53%+2.01%+44.05%+111.95% 25.4B
+2.44%+10.42%+10.77%+180.11% 21.43B
-0.76%-1.03%+57.98%+103.49% 15.77B
Average +1.37%+2.95%+85.63%+67.19% 42.9B
Weighted average by Cap. +1.97%+3.43%+108.32%+48.56%

Financials

2026 *2027 *
Net sales 8.69B 9.97B 8.19B 7.46B 13.98B 955B 14B 98.07B 37.8B 487B 37.46B 36.63B 1,570B 9.68B 11.1B 9.11B 8.3B 15.56B 1,063B 15.58B 109B 42.07B 542B 41.69B 40.77B 1,748B
Net income 1.93B 2.21B 1.82B 1.66B 3.11B 212B 3.11B 21.78B 8.4B 108B 8.32B 8.14B 349B 2.32B 2.67B 2.19B 1.99B 3.74B 255B 3.74B 26.22B 10.11B 130B 10.02B 9.79B 420B
Net Debt 306M 350M 288M 262M 491M 33.57B 492M 3.45B 1.33B 17.1B 1.32B 1.29B 55.18B -1.81B -2.07B -1.7B -1.55B -2.91B -199B -2.91B -20.39B -7.86B -101B -7.79B -7.62B -327B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
21/09/26 $233.86 -6.65% 429
18/09/26 $250.52 +1.37% 31
17/09/26 $247.14 -0.39% 37
16/09/26 $248.11 -0.99% 121
15/09/26 $250.59 -0.60% 237
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
212.10EUR
Average target price
285.00EUR
Spread / Average Target
+34.37%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!